These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
764 related articles for article (PubMed ID: 17785058)
41. Infections in immunocompromised patients. II. Established therapy and its limitations. Periti P; Mazzei T Clin Ther; 1985; 8(1):100-17. PubMed ID: 3854579 [TBL] [Abstract][Full Text] [Related]
42. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Chong Y; Yakushiji H; Ito Y; Kamimura T Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723 [TBL] [Abstract][Full Text] [Related]
43. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002. Kern WV; Steib-Bauert M; de With K; Reuter S; Bertz H; Frank U; von Baum H J Antimicrob Chemother; 2005 Jan; 55(1):57-60. PubMed ID: 15574472 [TBL] [Abstract][Full Text] [Related]
44. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Baskaran ND; Gan GG; Adeeba K Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382 [TBL] [Abstract][Full Text] [Related]
45. Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin. Yamamoto S; Ishitoya S; Segawa T; Kamoto T; Okumura K; Ogawa O Int J Urol; 2008 Jul; 15(7):604-6. PubMed ID: 18462354 [TBL] [Abstract][Full Text] [Related]
46. [Antibiotic prophylaxis in intensive care patients]. Pichler H Wien Klin Wochenschr Suppl; 1976; 52():3-24. PubMed ID: 1067690 [TBL] [Abstract][Full Text] [Related]
47. Antibacterial prophylaxis in patients with cancer and neutropenia. Almyroudis NG; Segal BH N Engl J Med; 2006 Jan; 354(1):90-4; author reply 90-4. PubMed ID: 16395832 [No Abstract] [Full Text] [Related]
48. Antibacterial prophylaxis in neutropenic patients. Viscoli C Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S60-5. PubMed ID: 17706926 [TBL] [Abstract][Full Text] [Related]
49. Antibacterial prophylaxis in patients with cancer and neutropenia. Freifeld AG; Sepkowitz KA; Martino P; Steven N; Billingham L; Cullen M; Baden LR N Engl J Med; 2006 Jan; 354(1):90-4; author reply 90-4. PubMed ID: 16394310 [No Abstract] [Full Text] [Related]
50. Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. Carlson JW; Fowler JM; Mitchell SK; Carson LF; Mayer AR; Copeland LJ Gynecol Oncol; 1997 May; 65(2):325-9. PubMed ID: 9159346 [TBL] [Abstract][Full Text] [Related]
51. Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract. Karp JE; Merz WG; Hendricksen C; Laughon B; Redden T; Bamberger BJ; Bartlett JG; Saral R; Burke PJ Scand J Infect Dis Suppl; 1986; 48():66-78. PubMed ID: 3535055 [TBL] [Abstract][Full Text] [Related]
52. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Eleutherakis-Papaiakovou E; Kostis E; Migkou M; Christoulas D; Terpos E; Gavriatopoulou M; Roussou M; Bournakis E; Kastritis E; Efstathiou E; Dimopoulos MA; Papadimitriou CA Am J Hematol; 2010 Nov; 85(11):863-7. PubMed ID: 20882526 [TBL] [Abstract][Full Text] [Related]
53. Single-drug oral antibacterial prophylaxis with ofloxacin in BMT recipients. Schmeiser T; Kern WV; Hay B; Hertenstein B; Arnold R Bone Marrow Transplant; 1993 Jul; 12(1):57-63. PubMed ID: 8374536 [TBL] [Abstract][Full Text] [Related]
54. Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia. Mayer K; Hahn-Ast C; Mückter S; Schmitz A; Krause S; Felder L; Bekeredjian-Ding I; Molitor E; Brossart P; von Lilienfeld-Toal M Support Care Cancer; 2015 May; 23(5):1321-9. PubMed ID: 25617073 [TBL] [Abstract][Full Text] [Related]
55. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. Malik I; Hussain M; Yousuf H J Infect; 2001 Feb; 42(2):120-5. PubMed ID: 11531318 [TBL] [Abstract][Full Text] [Related]
56. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. Verlinden A; Jansens H; Goossens H; van de Velde AL; Schroyens WA; Berneman ZN; Gadisseur AP Eur J Haematol; 2014 Oct; 93(4):302-8. PubMed ID: 24750350 [TBL] [Abstract][Full Text] [Related]
57. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Hori A; Kami M; Kim SW; Chizuka A; Kojima R; Imataki O; Sakiyama M; Hamaki T; Onishi Y; Usubuchi N; Kishi Y; Murashige N; Tajima K; Miyakoshi S; Heike Y; Masuo S; Taniguchi S; Takaue Y Biol Blood Marrow Transplant; 2004 Jan; 10(1):65-72. PubMed ID: 14752781 [TBL] [Abstract][Full Text] [Related]
58. [Comparative studies of DL-8280 and pipemidic acid in complicated urinary tract infections by double-blind method]. Kishi H; Nito H; Saito I; Nishimura Y; Niijima T; Ohmori H; Tanaka H; Fujita Y; Deguchi K; Ogawa N Hinyokika Kiyo; 1984 Sep; 30(9):1307-55. PubMed ID: 6395684 [TBL] [Abstract][Full Text] [Related]
59. Antibacterial prophylaxis in patients with cancer and neutropenia. Ito JI; Tegtmeier BR; O'Donnell MR N Engl J Med; 2006 Jan; 354(1):90-4; author reply 90-4. PubMed ID: 16395829 [No Abstract] [Full Text] [Related]
60. Antibacterial prophylaxis in patients with cancer and neutropenia. Castagna L; Santoro A N Engl J Med; 2006 Jan; 354(1):90-4; author reply 90-4. PubMed ID: 16395831 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]